449 related articles for article (PubMed ID: 30376881)
21. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
Ossenkoppele R; van der Kant R; Hansson O
Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092
[TBL] [Abstract][Full Text] [Related]
22. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
[TBL] [Abstract][Full Text] [Related]
23. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism.
Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M
J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446
[TBL] [Abstract][Full Text] [Related]
24. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study.
Whitwell JL; Dickson DW; Murray ME; Weigand SD; Tosakulwong N; Senjem ML; Knopman DS; Boeve BF; Parisi JE; Petersen RC; Jack CR; Josephs KA
Lancet Neurol; 2012 Oct; 11(10):868-77. PubMed ID: 22951070
[TBL] [Abstract][Full Text] [Related]
25. [Amyloid Positron Emission Tomography in the Therapeutic Strategies for Alzheimer's Disease].
Ishii K
Brain Nerve; 2017 Jul; 69(7):809-818. PubMed ID: 28739995
[TBL] [Abstract][Full Text] [Related]
26. Using machine learning to quantify structural MRI neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases.
Popuri K; Ma D; Wang L; Beg MF
Hum Brain Mapp; 2020 Oct; 41(14):4127-4147. PubMed ID: 32614505
[TBL] [Abstract][Full Text] [Related]
27. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.
Barrio JR; Kepe V; Satyamurthy N; Huang SC; Small G
J Nutr Health Aging; 2008 Jan; 12(1):61S-5S. PubMed ID: 18165848
[TBL] [Abstract][Full Text] [Related]
28. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
29. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
30. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
31. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
33. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
34. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
[TBL] [Abstract][Full Text] [Related]
35. PET amyloid-beta imaging in preclinical Alzheimer's disease.
Vlassenko AG; Benzinger TL; Morris JC
Biochim Biophys Acta; 2012 Mar; 1822(3):370-9. PubMed ID: 22108203
[TBL] [Abstract][Full Text] [Related]
36. Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging.
Lopes Alves I; Heeman F; Collij LE; Salvadó G; Tolboom N; Vilor-Tejedor N; Markiewicz P; Yaqub M; Cash D; Mormino EC; Insel PS; Boellaard R; van Berckel BNM; Lammertsma AA; Barkhof F; Gispert JD
Alzheimers Res Ther; 2021 Apr; 13(1):82. PubMed ID: 33875021
[TBL] [Abstract][Full Text] [Related]
37. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
38. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
39. Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders.
Raji CA; Torosyan N; Silverman DHS
J Alzheimers Dis; 2020; 77(3):935-947. PubMed ID: 32804147
[TBL] [Abstract][Full Text] [Related]
40. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]